Which drug class does Bortezomib belong to?

Bortezomib (Bortezomib) belongs to an important class of drugs classified as proteasome inhibitors (Proteasome Inhibitor). This class of drugs has unique therapeutic mechanisms and is widely used in cancer treatment, especially in the treatment of hematological malignancies.

The proteasome is a special structure within cells that is responsible for breaking down and degrading proteins. This process is important for maintaining protein balance within cells, as it removes old, damaged, or no longer needed proteins, while also maintaining normal cell metabolism and function by degrading proteins. However, cancer cells usually require more proteins to support their abnormal growth and proliferation, so they are highly dependent on the activity of the proteasome.

The pharmacological mechanism of action of bortezomib involves inhibition of proteasome function. By interfering with the proteasome, it is able to stop protein degradation inside cancer cells, causing protein accumulation in cancer cells, leading to the cessation of proliferation and eventual death of cancer cells. This targeted therapeutic mechanism makes bortezomib a highly effective anticancer drug, particularly suitable for the treatment of malignancies such as multiple myeloma and certain non-Hodgkin lymphomas.

Bortezomib is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of around 3,000 to 4,000 yuan. Please consult the local hospital pharmacy for specific prices and reimbursement policies. The cheaper ones abroad are mainly Indian generic drugs, which cost around 1,000 yuan and have basically the same ingredients as the domestic bortezomib drug.